Synchron Raises $200 Million Series D to Advance Brain-Computer Interface Technology
Synchron has secured $200 million in Series D funding to accelerate the commercialization of its Stentrode™ brain-computer interface (BCI) platform. The investment will also support the expansion of the company’s AI and engineering teams in New York and San Diego.
Funding Purpose and Impact
- Advance the Stentrode™ BCI technology towards broader market availability.
- Expand artificial intelligence capabilities and engineering operations.
- Strengthen company presence in New York and San Diego.
About the Stentrode™ Device
The Stentrode™ is an endovascular electrode array designed to connect the brain to external devices, enabling new possibilities in medical technology and patient care.
Photo caption: The Stentrode™ Endovascular Electrode Array
Photo credit: Synchron
Media Contact
Kimberly Ha — [email protected]
Summary: Synchron’s $200 million Series D funding will accelerate the delivery of its innovative Stentrode™ brain-computer interface while expanding AI and engineering teams in key U.S. locations.